The aim of the present study was to assess the association between anticholinergic (atropinic) burden and cognitive decline in older adults over the course of 3 years.
Introduction
With an ageing population worldwide (617 million people aged ≥65 years) [1] , promoting healthy ageing has become a priority for the World Health Organization [2] . In this context, it is important to improve our knowledge about factors that might alter cognitive function in older adults, including medications. Anticholinergic (atropinic) drugs are frequently used in various indications, such as depression, pain or allergy, and 7.5-48% of community-dwelling older adults are exposed to these drugs [3, 4] . These agents block muscarinic receptors, which can lead to adverse reactions such as urinary retention, dry mouth, delirium [5] or cognitive dysfunction [6, 7] . Older adults are particularly prone to such adverse reactions because age affects the pharmacodynamics and pharmacokinetics of anticholinergic drugs [8, 9] .
Although all anticholinergic drugs antagonize muscarinic receptors, their likelihood of inducing anticholinergic adverse effects depends on each drug's individual properties (potency, inhibition, receptor affinity, bioavailability, ability to cross the blood-brain barrier, and so forth.).
Several anticholinergic drug scales have been proposed for measuring the 'anticholinergic score' of a drug, which corresponds to its anticholinergic potency. Some are based on biological methods -i.e. the measurement of serum anticholinergic activity via a binding assay [10] -while the others are clinical scales, of which there are more than 10 [11] [12] [13] [14] [15] . The most commonly used are the Anticholinergic Drug Scale (ADS) [16] , Anticholinergic Cognitive Burden (ACB) scale [17] , Anticholinergic Risk Scale (ARS) [18] and the Durán list [19] . Scores on these scales generally vary between 0 (no anticholinergic potency) and 4 (strong anticholinergic potency), with discrepancy in the definition of anticholinergic exposure and anticholinergic score estimations for a given drug, depending on the scale used. Only moderate concordance has been found between five anticholinergic scales in older adults [20] . This could lead to variability in anticholinergic drug exposure measurement across studies.
Furthermore, measuring anticholinergic scores during concomitant exposure, known as the ʻanticholinergic (atropinic) burdenʼ, is a challenge. Indeed, when an individual is simultaneously exposed to multiple anticholinergic medications, there is no consensual way to measure the global anticholinergic burden or the burden over time. Some authors [16] [17] [18] have recommended summing the anticholinergic score of individual concomitant anticholinergic drugs to obtain the total anticholinergic burden, but the pharmacological plausibility of different options is questionable [21] .
Many cross-sectional studies have reported a relationship between anticholinergic exposure and impaired cognitive function. [22] . However, such designs are not well suited to assess this association. Moreover, some longitudinal studies [11, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] have been conducted but results were discordant, and they used various anticholinergic exposure measures but rarely measured anticholinergic burden.
The aim of our study was to analyse the effect of longitudinal anticholinergic burden on cognitive decline in older adults during a 3-year study. Furthermore, we aimed to assess the effect of using various methods of anticholinergic exposure measurements (anticholinergic burden scale, measures of anticholinergic exposure) on our results.
Methods

Setting and population
We analysed subjects enrolled in a multicentre randomized controlled trial, the Multidomain Alzheimer Prevention Trial (MAPT) [43, 44] . Briefly, the primary objective of MAPT was to analyse the effect of an omega 3 supplement and/or multidomain intervention (physical exercise, cognitive training, nutritional recommendations and prevention consultations) on cognitive function among community-dwelling French adults aged 70 years. Recruitment was via hospital centres, memory clinics, general practitioners, media, conferences on healthy ageing, word of mouth, and health care services. Subjects were included if they presented a spontaneous memory complaint, slow gait speed (<0.8 m s -1 ) or a limitation in at least one of the Instrumental Activities of Daily Living (IADL). Between 2008 and 2011, 1680 subjects without dementia (Mini Mental State Examination score >23) or a disability in the basic activities of daily living were included in 13 centres, and randomized into four groups: omega-3 supplement alone, omega-3 supplement and multidomain intervention, multidomain intervention and placebo, placebo alone. The study was approved by the local ethics committee, and written informed consent was obtained for all subjects.
Drug exposure assessment
Prescribed and over-the-counter drugs were self-reported at baseline, and any modification in medications was recorded during 6-month follow-up visits over the course of 3 years.
If self-reports of drug exposure were considered unreliable, the next of kin was also interviewed. Drug initiation and discontinuation dates were also collected. Drug exposure was recorded as trade or international generic names and then coded using the World Health Organization's Anatomical Therapeutic Chemical classification [45] .
Anticholinergic definition and anticholinergic score
We used four anticholinergic burden scales:
• The Durán list [19] , the most recent scale, published in 2013 and developed from a review of English-language anticholinergic burden scale papers. Drugs are assigned an anticholinergic score of 0, 1 (low potency) or 3 (high potency) [46] . • The ADS [16] , developed in the USA in 2006, scoring drugs from 0 to 3 (1: potency demonstrated in vitro; 2: potency sometimes noted; 3: potency demonstrated).
• The ACB scale [17] , developed in the USA in 2008, also scores drugs from 0 to 3 (1: possible effect; 2: moderate effect; 3: severe effect).
• The ARS [18] , developed in the USA in 2008, again, scores drugs from 0 to 3 (1: low potency; 2: moderate potency; 3: high potency). In sensitivity analysis, we included drugs available on the French market that had not been considered in these four scales because of a lack of drug availability, and evaluated their anticholinergic score based on our pharmacological and clinical experience, creating four modified anticholinergic burden scales [adding between four and eight drugs with anticholinergic properties (see Table A4 )].
Measure of anticholinergic burden
We used four definitions of anticholinergic exposure. Three of these were assessed at each visit and considered as timevarying in statistical analyses. Two of these definitions took into account the anticholinergic score:
• Anticholinergic use defined by the maximal anticholinergic score of any anticholinergic drugs used by the participant, categorized into 2-3 classes: 1, 2 (for ADS, ACB, ARS scales only) or 3.
• Anticholinergic use based on the sum of all anticholinergic drug scores, secondarily dichotomized in two groups: 1-3 or >3.
The third did not take into account the anticholinergic score:
• Use of at least one anticholinergic drug (whatever the score).
The fourth definition, which is widely used in the literature, did not take into account the anticholinergic score, and was considered as a time constant variable in statistical analyses:
• Use of at least one anticholinergic drug (whatever the score) at baseline. Moreover, we conducted a sensitivity analysis for our third definition, with anticholinergic use defined as at least one anticholinergic drug at each visit in new users of anticholinergic drugs.
Cognitive function assessment
Trained staff assessed cognitive function at baseline, and at 6-, 12-, 24-and 36-month visits, using the following neurocognitive tests, each of which was related to different cognitive subdimensions:
• Orientation was analysed by the orientation section of the MMSE (the first 10 questions) [47] , scored between 0 and 10.
• Episodic memory was measured with the total and free recall scores of the Free and Cued Selective Reminding Test [48] , scored between 0 and 96.
• Executive function and attention were assessed by the Digit Symbol Substitution Test from the Wechsler Adult Intelligence Scale-Revised (WAIS-R), scored between 0 and 93 [49] .
• Verbal fluency was analysed by the Category Naming Test [50] . The participant's score corresponded to the number of correct words belonging to the predefined category expressed over a period of 2 min.
For all of these tests, higher scores indicate better cognitive function. For each participant and visit, each score from these four subdimensions was transformed secondarily to a z-score (z-score = (observed score -mean baseline score) / baseline standard deviation).
A composite z-score was then calculated as the mean of the four z-scores for the four cognitive subdimensions. This score, which was the primary outcome of the MAPT trial, was considered to be sensitive to cognitive change in participants with normal cognition [51, 52] .
Definition of cognitive decline
Cognitive decline was defined by a cut-off based on cognitive change on the composite z-score during the first year. The same cut-off to changes in the composite z-score was applied during the second and the third year. Participants who declined by more than this cut-off, during at least one of the three annual follow-up periods, were considered as cognitive decliners.
Various other cut-offs were considered. In our primary analysis, we used a cut-off based on the lowest quintile of cognitive change during the first year, representing, in this population, a decline of À0.236 points (i.e. 20% of the population declined by more than this cut-off during the first 12 months).
We defined other cognitive decline cut-offs based on the lowest quartile (À0.153 points) and decile (À0.446 points) at 12 months. We also used a cut-off of À0.300 points, which has been found to be clinically relevant in previous literature [53] .
Cognitive decline and handling of missing variables
We included participants who completed the four neuropsychological tests during at least one follow-up visit (12, 24 or 36-month visits).
Missing cognitive scores were imputed for each neuropsychological test at each visit by using mixed linear regression models adjusted for age, sex and level of education (<4% of data were imputed). We excluded participants with missing data for one of these three covariates (n = 24).
Statistical analysis
Descriptive analysis. We compared the baseline characteristics of cognitive decliners and nondecliners using t-tests or Mann-Whitney-Wilcoxon tests for continuous variables and chi-square or Fisher exact tests for categorical variables.
Analysis of the relationship between anticholinergic exposure and cognitive decline. Multivariable Cox proportional hazard models were used to compute hazard ratios (HRs) and 95% confidence intervals for the relationship between anticholinergic exposure and cognitive decline during the 36 months of follow-up. Anticholinergic exposure was considered as a time-varying or time-constant variable, depending on the definition of anticholinergic exposure used, and exposure to non-anticholinergic drugs was considered as time varying in all models.
Covariates identified in the literature as being associated with cognitive decline [neurological history or comorbidity, Geriatric Depression Scale (GDS) and level of education], as well as variables associated with cognitive decline with a P-value <0.2 in bivariate analyses, were included in the initial multivariable model. The proportional hazards assumption was checked for time-constant variables.
A manual backward stepwise procedure was used to select our final model, controlling for confounding in each step. This selection was conducted on one model (anticholinergic exposure defined by the maximal anticholinergic score for the Durán list, cognitive decline based on the quintile) and the same adjustment was used for other exposure definitions and other anticholinergic scales.
Our final model was stratified by centre and adjusted for age, sex, level of education, limitations in IADLs [54] , high blood pressure, frailty status, according to Fried criteria [55] (robust, prefrail or frail), neurological history or comorbidity, cardiovascular history or comorbidity, symptomatology suggestive of depression using the GDS [56] , baseline cognitive impairment using the Clinical Dementia Rating (CDR) [57] and number of drugs used (with the exception of anticholinergic drugs) at each visit (0, 1-4 or ≥5 drugs, corresponding to one definition of polymedication [58] ).
Sensitivity analyses. Sensitivity analyses were performed in which: (i) varying definitions of cognitive decline were used [(a) without imputed cognitive scores; (b) using quartile, decile and À0.3 point cut-offs]; (ii) different anticholinergic Figure 1 Flow chart of the included subjects Anticholinergic exposure and cognition scales were used, including modified scales for French drugs; (iii) analyses were restricted to new users of anticholinergic drugs; and (iv) alternative covariates were used for adjustment (including apolipoprotein E4, which was not used in the primary analyses owing to relatively high rates of missing data). Analyses were conducted using STATA software 14 (StataCorp, College Station, TX, USA). Tables A1 and A2 ). Excluded participants also appeared more exposed to anticholinergic Table 3 Main anticholinergic drugs used at baseline in participants who did and did not undergo cognitive decline at any time during follow-up a (N = 1396) Baseline cognitive scores in participants who did and did not undergo cognitive decline at any time during follow-up a (N = 1396)
Results
Description of the population
Participants with no cognitive decline (N = 504) Participants with cognitive decline (N = 504) medications, irrespective of the anticholinergic scales used, than those who were included (18.0% vs. 16.0%, using the Durán list, P = 0.427) but this difference was not significant.
Cognitive decline
Using the quintile definition at 12 months, which defined 20% of our population (280 participants) as decliners, the cut-off for cognitive decline was À0.236 points on the composite z-score. Between 12 and 24 months, 396 participants declined by 0.236 points or more, and 216 additional participants declined by this amount or more between 24 and 36 months. Therefore, 64% (n = 892) of the participants displayed cognitive decline at any time (Table 1) . At baseline, non-decliners had significantly better cognitive function on the MMSE and on the Free and Cued Selective Reminding Test (Table 2 ) and less initial cognitive impairment on the CDR compared with the cognitive decliners ( Table 1) .
Anticholinergic exposure
The proportion of prevalent anticholinergic drug users at baseline depended on the anticholinergic burden scale used: 7.4% using ARS, 16.0% using the Durán list, 21.9% using the ACB and 23.5% using the ADS. Anticholinergic drug users (for the Durán list) had a lower level of education, a lower composite cognitive z-score and were more exposed to non-anticholinergic drugs (Table A3) . Tramadol, furosemide, dextropropoxyphene and paroxetine were the most commonly used anticholinergic drugs (Table 3 ). The population was mostly exposed to drugs with low anticholinergic scores (i.e. 1) (Figure 2A ). During follow-up, the prevalence of anticholinergic drug use increased at the 6-month visit, and remained stable during other followup visits (ranging from around 8-9% using the ARS to 28-29% using the ADS). Most participants had a low anticholinergic burden (i.e. 1) during follow-up. Between 8.3% (for the ARS) and 19.4% (for the ADS) of participants started using anticholinergic drugs during the follow-up ( Figure 2B ).
Anticholinergic exposure and cognitive decline
At baseline, anticholinergic exposure among cognitive decliners was not significantly different than among the noncognitive decliners (15.5 vs. 17.1%, respectively, using the Durán list; P = 0.436) ( Figure 2C ). A similar trend was observed for all anticholinergic burden scales ( Figure 2B ,C,D). Results from the multivariate Cox analyses are presented in Table 4 . Regardless of the burden scale used or the definition of anticholinergic exposure, there was no association between anticholinergic exposure and cognitive decline. For the primary analysis (maximal score estimated using the Durán list, with the quintile definition of cognitive decline), neither the use of a maximal anticholinergic score of 1 [HR = 1.14, 95% confidence interval (CI) = (0.95, 1. In sensitivity analyses conducted using alternative cut-offs for cognitive decline, the results remained stable (see Tables A6-A11) , and we only identified five significant associations between anticholinergic exposure and cognitive decline: compared with non-anticholinergic drug users, participants with a maximal ARS score of 1 had a significantly greater risk of cognitive decline using the quartile (HR = 1.33; P = 0.048), decile (HR = 1.49; P = 0.029) and quintile (restricted to new users of anticholinergic drugs) (HR = 1.63; P = 0.033) definitions, as did participants exposed to a maximal ACB score of 3 with the decile (HR = 1.55; P = 0.007) and quintile (restricted to non-anticholinergic drug users at baseline (HR = 5.43; P = 0.020) cognitive decline definitions (see Tables A6-A12 ).
Discussion
In our study, 7.4-23.5% of participants were exposed to anticholinergic drugs at baseline, depending on the scale used. One of the study's objectives was to compare different definitions of anticholinergic exposure, but we were not able to detect any association between anticholinergic exposure and cognitive decline, regardless of the anticholinergic scale used and the method of assessing anticholinergic exposure. Results were stable during sensitivity analyses, in particular when using various cut-offs to define cognitive decline. As expected, the prevalence of anticholinergic exposure depended on the anticholinergic burden scale used and varied by more than threefold at baseline across the different scales. The prevalence was highly dependent on the number of drugs listed in the scale (e.g. 49 in the ARS vs. 117 in the ADS). This variability is in line with the work of Naples et al. [20] , who found a prevalence of exposure of 23%, 43% and 51%, respectively, using the ARS, ADS and ACB in Americans aged between 70 years and 79 years who were without a mobility disability, corresponding to a concordance between scales varying between 0.43 and 0.65 (moderate concordance). This is also in line with an Australian study [59] which found a concordance varying between 0.263 and 0.628 (low to moderate concordance) between scales in community-dwelling men aged 70 years and over.
We found a lower prevalence of anticholinergic exposure in MAPT participants compared with previous studies using comparable anticholinergic burden scales in older adults [20, 24, 40, 60] . However, comparison with the literature is difficult, as most studies included both institutionalized and community-dwelling participants [24] , or specific populations (e.g. male veterans [40] ).
In our study, we analysed global cognition using a composite z-score. The effect of anticholinergic exposure on global cognition has not been widely studied in the literature. Shah et al. [39] tested a composite z-score of 19 neuropsychological tests in well-educated and healthy older American Catholic nuns, priests or lay brothers at 10 years. They found no association between anticholinergic exposure and cognition in prevalent users compared with non-anticholinergic drug users. However, incident anticholinergic users declined, on average, by À0.34 z-score units per year more than nonusers (P < 0.001). This discrepancy might be explained by a longer follow-up period, a higher incidence of exposure, a healthier population and the use of a mixed linear model based on the difference in cognitive change at 10 years, and not the incidence of cognitive decline.
Other studies analysed global cognition using the MMSE or Saint Louis University Mental Status (SLUMS) examination [24, 29, 30, 32-34, 36, 40] , but results were inconsistent: one study [40] found a significant association between baseline anticholinergic exposure and cognition measured with MMSE progression, whereas two studies with longer follow-ups found no association [29, 34] . One study evaluated baseline Anticholinergic exposure and cognition anticholinergic burden and MMSE progression at 2 years in community-dwelling adults aged 65 years or older in the UK [24] . The authors found significant MMSE deterioration after 2 years of follow-up for those exposed to a maximal score >1, but this result did not remain significant when using the sum of anticholinergic scores compared with non-users. Some studies have assessed the association between longitudinal anticholinergic exposure and cognitive function. A significant association was found between sustained anticholinergic exposure during the 2-and/or the 4-year visits and a decrease in the MMSE score at 4 years in one study [29] . Discontinuation of anticholinergic drugs was also found to be associated with cognitive function improvement, based on the SLUMS examination in another study [30] . Lastly, Jamsen et al. [32] evaluated the association between longitudinal anticholinergic burden (measured by the sum of anticholinergic scores during three visits and treated as a time-varying exposure in the analysis) and MMSE evolution in ≥70-year-old community-dwelling men. Anticholinergic burden was associated with a slightly lower MMSE score at 5 years compared with non-anticholinergic users but there was no difference in the rate of MMSE decline.
Two longitudinal studies reported a significant association of anticholinergic use with other cognitive outcomes:
one found an association with fluency, attention, visuospatial ability and mild cognitive impairment incidence in nondemented community-dwelling adults aged >60 recruited from general practice (GP) patients [11] , and another with dementia incidence (Diagnostic and Statistical Manual of Mental Disorders-IV definition) in non-nursing-home residents and nondemented adults aged ≥75 recruited from GP registries [23] compared with non-anticholinergic users. However, other studies reported no association or inconsistent results, depending on the neuropsychological tests, the cognitive definition (cognitive score or cognitive trajectory) and the anticholinergic burden scale used, or the covariables included [11, 25, 33, 36, 37] .
As in our study, some other studies also compared different anticholinergic exposure measures [11, 33, 36] . Low et al. [36] found no association between longitudinal anticholinergic exposure and cognitive change on the MMSE at 4 years in community-dwelling older adults without dementia, using two methods to assess anticholinergic exposure: (i) any anticholinergic use; and (ii) burden defined by the sum of anticholinergic scores (compared with the nonanticholinergic users). Likewise, Kashyap et al. [33] used the value obtained when each baseline anticholinergic score (sum of scores) was subtracted from its 1-year follow-up Table 4 Hazard ratios for cognitive decline Anticholinergic exposure and cognition anticholinergic score defined by the ACB, the ARS or the ADS scales in nondemented and nondepressed patients included in incontinence clinics, and found no association with 1-year MMSE change, measured using three methods. Our main hypothesis was that anticholinergic burden would be associated with cognitive decline. However, we observed no such association. Some limitations or other factors might explain this result. Firstly, we defined cognitive decline using a statistical method, and 64% of our population experienced cognitive decline during follow-up with this definition (cut-off at À0.236 points). As most participants presented cognitive decline using this definition, it might have been too sensitive to detect a difference between groups. Moreover, we applied the value obtained at 1 year to other 1-year periods during follow-up, assuming a constant decline over time, which could be questionable as learning effects (i.e. an increase in cognitive scores from baseline to the first followup visits) have been reported [61] , although the neuropsychological tests used in our study were standardized and performed by trained staff. Furthermore, the clinical relevance of such a change needs to be further evaluated, even though it was of similar magnitude to a level of decline previously reported as clinically relevant in the literature [53] . However, we conducted multiple sensitivity analyses, all of which gave stable results. Furthermore, anticholinergic drugs might have cognitive effects on some specific subdimensions of cognitive function which were not assessed in our study, such as visuospatial abilities [11] . Secondly, cognitive decliners were less frequently exposed to anticholinergic drugs than noncognitive decliners at baseline, and this trend was stable during follow-up visits. However, we observed a higher incidence of anticholinergic drug use among cognitive decliners, which is in line with our hypotheses. In addition, we could not confirm whether baseline anticholinergic drug users were prevalent or incident users. The lower prevalence of anticholinergic drug use among future cognitive decliners might suggest a potential ʻdepletion of the susceptiblesʼ phenomenon [62] . To investigate this hypothesis further, we evaluated the anticholinergic exposure among incident users with cognitive function; this found an association with cognitive decline among anticholinergic users for a sum >3 using the ACB [17] compared with non-users. The ACB has been developed from a review of drugs that are specifically likely to cause cognitive impairment based on blood-brain barrier permeability. The ACB scale might therefore be more suited to answer our research question. Longer follow-up would be informative, particularly among new users of anticholinergic drugs. Moreover, in some analytical categories, such as the number of incident users, the number of participants was small during follow-up. We were also limited by the length of the follow-up. Thirdly, drug exposure was self-reported, meaning that classification bias cannot be excluded. However, a proxy confirmation could have been sought in the presence of unreliable self-reports. In addition, we were not able to take into account the duration of exposure and dose of anticholinergic drug used, and therefore could not use other measures such as the Drug Burden Index scale [63] . A recent study [42] that was able to take into account duration and dose found a significant association with the incidence of dementia for a follow-up period of ≥4 years. However, an advantage of our study was that we included over-the-counter drugs, which has seldom been done in previous studies. Fourthly, a Cox regression analysis with time-varying variables implied a relationship between cognitive function and short-term anticholinergic exposure (analysis of the last exposure known before each event), whereas a long-term or cumulative anticholinergic exposure might be important. However, when studying the association between cumulative anticholinergic exposure and cognitive progression in multivariate mixed linear regression models, we found no statistically significant relationship using the four scales and various exposure measures, except when considering the ARS scale for one measure (the maximal score compared with the nonusers; data not shown). Lastly, our results might not be applicable in the general older population, as our population volunteered to participate in a randomized clinical trial, was well educated, had a low exposure to polypharmacy or anticholinergic drugs, and had good cognitive performance at baseline. Overall, our population was at a relatively low risk of developing cognitive impairment during the 3 years of follow-up, despite memory complaints expressed at baseline.
Conclusion
In this large, nationwide, longitudinal study, we found no association between anticholinergic exposure and 3-year cognitive decline in adults aged 70 years or older. These results remained consistent using four anticholinergic burden scales and four measures of anticholinergic exposure. Nevertheless, anticholinergic drugs should be prescribed with caution in older individuals, as anticholinergic exposure has been associated with clinically relevant events [64, 65] . The harm-benefit balance should be evaluated and alternatives considered, particularly in cases of multiple/high anticholinergic exposure. Further studies, with longer follow-up and in other populations, such as middle-aged adults with a low level of education, who are at risk of cognitive decline and anticholinergic exposure [24, 60, 66] , could help to address further the relationship between anticholinergic drug use and cognitive decline. Table A5 Additional French drugs added to modified anticholinergic burden scales 
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